A randomised, multicenter, multinational Phase II study on trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab versus pertuzumab and docetax...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-001105-13

A randomised, multicenter, multinational Phase II study on trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab versus pertuzumab and docetaxel in patients with locally advanced, inflammatory or early stage HER2 positive breast cancer

Femme Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To make a preliminary assessment of the efficacy of neoadjuvant treatment of trastuzumab and docetaxel as compared to trastuzumab, pertuzumab and docetaxel as compared to trastuzumab and pertuzumab and pertuzumab and docetaxel compared to trastuzumab, pertuzumab and docetaxel, in patients with T2-4d HER2 positive breast cancer, based on complete pathological response rate.


Critère d'inclusion

  • Locally advanced, inflammatory or early stage HER2 positive breast cancer